PriceTargets.com logo

Dechra Pharmaceuticals - DPH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 3,672
  • Forecasted Upside: 0.47%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
GBX 3,655 As of 06/2/2023 01:45 PM ET
▲ +281 (8.33%)

This chart shows the closing price for DPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dechra Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DPH

Analyst Price Target is GBX 3,672
▲ +0.47% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Dechra Pharmaceuticals in the last 3 months. The average price target is GBX 3,672, with a high forecast of GBX 4,070 and a low forecast of GBX 2,850. The average price target represents a 0.47% upside from the last price of GBX 3,655.

This chart shows the closing price for DPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Dechra Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/25/2023Deutsche Bank AktiengesellschaftReiterated RatingOutperformGBX 4,070
5/22/2023Numis SecuritiesReiterated RatingBuyGBX 4,000
3/7/2023JPMorgan Chase & Co.Lower TargetOverweightGBX 4,600 ➝ GBX 4,000
2/28/2023Jefferies Financial GroupReiterated RatingBuyGBX 3,112
2/27/2023Berenberg BankReiterated RatingHoldGBX 2,850
10/5/2022Berenberg BankReiterated RatingHoldGBX 2,850
9/15/2022Royal Bank of CanadaLower TargetOutperformGBX 4,200 ➝ GBX 4,000
9/7/2022JPMorgan Chase & Co.Reiterated RatingOverweightGBX 5,700
7/5/2022Royal Bank of CanadaUpgradeOutperformGBX 5,300 ➝ GBX 4,200
2/23/2022Liberum CapitalUpgradeHoldGBX 4,000 ➝ GBX 4,020
2/4/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 5,300
1/4/2022JPMorgan Chase & Co.Boost TargetOverweightGBX 5,400 ➝ GBX 5,700
12/7/2021Liberum CapitalReiterated RatingSellGBX 3,960
12/3/2021Royal Bank of CanadaBoost TargetSector PerformGBX 4,400 ➝ GBX 5,300
11/3/2021Liberum CapitalReiterated RatingSellGBX 3,960
9/7/2021Liberum CapitalBoost TargetSellGBX 3,110 ➝ GBX 3,960
6/9/2021Royal Bank of CanadaBoost TargetSector PerformGBX 3,600 ➝ GBX 4,400
3/11/2021Royal Bank of CanadaBoost TargetSector PerformGBX 3,450 ➝ GBX 3,600
7/22/2020Jefferies Financial GroupBoost TargetBuyGBX 3,185 ➝ GBX 3,515
6/5/2020JPMorgan Chase & Co.Lower TargetOverweightGBX 3,300 ➝ GBX 3,200
6/4/2020Royal Bank of CanadaLower TargetSector PerformerGBX 2,560 ➝ GBX 2,510
4/24/2020HSBCBoost TargetHoldGBX 3,020 ➝ GBX 3,085
3/20/2020Royal Bank of CanadaBoost TargetSector PerformerGBX 2,530 ➝ GBX 2,560
3/13/2020Royal Bank of CanadaBoost TargetSector PerformerGBX 2,500 ➝ GBX 2,530
2/25/2020JPMorgan Chase & Co.Boost TargetOverweightGBX 3,200 ➝ GBX 3,300
1/21/2020Jefferies Financial GroupDowngradeHoldGBX 3,090 ➝ GBX 2,930
1/6/2020JPMorgan Chase & Co.Lower TargetOverweightGBX 3,500 ➝ GBX 3,200
12/2/2019HSBCBoost TargetHoldGBX 2,915 ➝ GBX 2,950
9/4/2019JPMorgan Chase & Co.Boost TargetOverweightGBX 3,000 ➝ GBX 3,500
9/2/2019Royal Bank of CanadaBoost TargetSector PerformGBX 2,100 ➝ GBX 2,500
3/25/2019Jefferies Financial GroupBoost TargetBuyGBX 2,466 ➝ GBX 2,805
3/25/2019JPMorgan Chase & Co.Initiated CoverageOverweightGBX 3,000
3/11/2019HSBCLower TargetBuyGBX 2,770 ➝ GBX 2,700
2/12/2019HSBCInitiated CoverageBuyGBX 2,770
11/23/2018Royal Bank of CanadaLower TargetSector PerformerGBX 2,400 ➝ GBX 2,100
9/3/2018Numis SecuritiesDowngradeHold
7/10/2018Numis SecuritiesBoost TargetAddGBX 2,640 ➝ GBX 2,950
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Dechra Pharmaceuticals logo
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More

Today's Range

Now: GBX 3,655
Low: 3,628
High: 3,949

50 Day Range

MA: GBX 3,305.16
Low: 2,558
High: 3,777.86

52 Week Range

Now: GBX 3,655
Low: 2,473.32
High: 3,949

Volume

9,929,383 shs

Average Volume

858,720 shs

Market Capitalization

£4.16 billion

P/E Ratio

10,152.78

Dividend Yield

1.43%

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Dechra Pharmaceuticals?

The following Wall Street research analysts have issued reports on Dechra Pharmaceuticals in the last year: Berenberg Bank, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., Numis Securities Ltd, and Royal Bank of Canada.
View the latest analyst ratings for DPH.

What is the current price target for Dechra Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Dechra Pharmaceuticals in the last year. Their average twelve-month price target is GBX 3,672, suggesting a possible upside of 0.5%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting DPH will reach GBX 4,070 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of GBX 2,850 for Dechra Pharmaceuticals in the next year.
View the latest price targets for DPH.

What is the current consensus analyst rating for Dechra Pharmaceuticals?

Dechra Pharmaceuticals currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DPH will outperform the market and that investors should add to their positions of Dechra Pharmaceuticals.
View the latest ratings for DPH.

What other companies compete with Dechra Pharmaceuticals?

Other companies that are similar to Dechra Pharmaceuticals include Vectura Group, Hikma Pharmaceuticals, Mediclinic International, ConvaTec Group and BTG. Learn More about companies similar to Dechra Pharmaceuticals.

How do I contact Dechra Pharmaceuticals' investor relations team?

Dechra Pharmaceuticals' physical mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company's listed phone number is +44-1606-814730. The official website for Dechra Pharmaceuticals is www.dechra.com. Learn More about contacing Dechra Pharmaceuticals investor relations.